Phosphodiester oligonucleotides inhibit mitosis and trigger apoptosis by a non-antisense, p53-mediated mechanism

Antisense and Nucleic Acid Drug Development

Volumn 12, Issue 1, 2002, Pages 21-31

  Papucci, Laura ^a   Schiavone, Nicola ^a   Donnini, Martino ^a   Lapucci, Andrea ^a   Luzi, Ettore ^a   Tempestini, Alessio ^a   Witort, Ewa ^a   Capaccioli, Sergio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DOUBLE STRANDED DNA; OLIGODEOXYRIBONUCLEOTIDE; ORGANOPHOSPHATE; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; GENETIC TRANSFECTION; MITOSIS INHIBITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANIMALIA;

EID: 0036239950     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729002753670238     Document Type: Article

References (50)

1. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and stranded transfer
2. P53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain
3. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients
4. A good antisense molecule is hard to find
5. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
6. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum
7. Induction of apoptosis in fibroblasts by c-myc protein
8. A transcriptionally active DNA-binding site for human p53 protein complexes
9. Blockade of clomipramine and amitriptyline analgesia by an antisense oligonucleotide to mKv1.1, a mouse Shaker-like potassium channel
10. An antisense oligonucleotide on the mouse Shaker-like potassium channel Kv1.1 gene prevents antinociception induced by morphine and baclofen
11. Effects of potassium channels modulation on mouse feeding behavior
12. Antisense knock down of M1 receptors induces transient anterograde amnesia in mice
13. P53 in growth control and neoplasia
14. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
15. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of cpg oligonucleotides
16. Adaptive recognition by nucleic acid aptamers
17. 1 arrest
18. Allosteric activation of latent p53 tetramers
19. Activation of p53 sequence specific DNA binding by short single stranded of DNA requires the p53 C-terminus
20. Participation of p53 protein in the cellular response to DNA damage
21. Therapeutic applications of CpG-containing oliggodeoxynucleotides
22. Direct immunologic activities of CpG DNA and implications for gene therapy
23. The role of CpG motifs in innate immunity
24. From bugs to drugs: Therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA
25. CpG motifs in bacterial DNA trigger direct B-cell activation
26. Apoptosis, cancer and the p53 tumor suppressor gene
27. P53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches
28. CpG stimulation primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation
29. Reversible antisense inhibition of Shaker-like Kv1.1 potassium channel expression impairs associative memory in mouse and rat
30. The bcl-2/IgH antisense transcript is an optimal target for synthetic oligonucleotides
31. Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides
32. Application of transcription factor "decoy" strategy as a means of gene therapy and study of gene expression in cardiovascular disease
33. DNA stranded breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways
34. Induced N- and C-terminal cleavage of p53: A core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53
35. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance in neoplastic cells
36. Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids
37. Enhancing antisense oligonucleotide intracellular levels by means of cationic lipids as vectors
38. Antimessenger oligonucleotide for urokinase receptor gene inhibits invasivity of transformed human fibroblasts
39. Reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibiting the urokinase receptor gene expression
40. Induction of apoptosis and mitosis inhibition by degraded DNA lipofection mimicking genotoxic drug effects
41. The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region
42. Enhanced p53 activity and accumulation in response to DNA damage upon DNA transfection
43. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides
44. Oligodeoxynucleotide 5-mers containing a 5′-CpG induced apoptosis through mitochondrial mechanism in T lymphocytic leukaemia cells
45. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA agents
46. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides
47. p53 domains: Identification and characterization of two autonomous DNA binding regions
48. Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB
49. A functional p53-responsive intronic promoter is contained within the human mdm2 gene
50. P53 C-terminal interaction with DNA ends and gaps has opposing effects on specific DNA binding by the core